Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureNathaly Vasquez-Martínez, Alejandro Sosa-Peinado, Francisco Cortés-Benítez, Martín González-Andrade
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling
10.1074/jbc.271.33.19810 · 1996
TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B
10.1074/jbc.c100583200 · 2001
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer
10.1158/0008-5472.can-06-4610 · 2007
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling
10.1182/blood-2008-03-148726 · 2008
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients
10.1080/15384101.2014.998047 · 2015
Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome
10.18632/oncotarget.7829 · 2016
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT
10.1007/s13277-016-5245-1 · 2016
Organoplatinum(II) type II immunogenic cell death inducers target protein tyrosine phosphatase 1B to drive immunogenicity
10.1021/jacs.5c18904 · 2026
Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands
10.1021/jm034088d · 2003
Drug repurposing as an effective drug discovery strategy: a critical review
10.2147/dddt.s576701 · 2025
Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor
10.1021/acsmedchemlett.9b00568 · 2020
BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells
10.1016/j.bcp.2023.115738 · 2023
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
10.1038/s41418-024-01417-z · 2025
PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity
10.1158/2159-8290.cd-21-0694 · 2022
BH3 mimetics derived from Bim-BH3 domain core region show PTP1B inhibitory activity
10.1016/j.bmcl.2018.11.047 · 2019
Discovery of novel PTP1B inhibitors derived from the BH3 domain of proapoptotic Bcl-2 proteins with antidiabetic potency
10.1021/acsmedchemlett.1c00174 · 2021
Allosteric regulation of the tyrosine phosphatase PTP1B by a protein-protein interaction
10.1002/pro.70016 · 2025
Quantitative proteomics identifies PTP1B as modulator of B cell antigen receptor signaling
10.26508/lsa.202101084 · 2021
The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to bad
10.1002/1521-4141(200207)32:7<1847::aid-immu1847>3.0.co;2-7 · 2002
AlphaFold2 modeling and molecular dynamics simulations of an intrinsically disordered protein
10.1371/journal.pone.0301866 · 2024
Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs
10.1002/1873-3468.14901 · 2024
Native dynamics and allosteric responses in PTP1B probed by high-resolution HDX-MS
10.1002/pro.5024 · 2024
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor
10.1038/nchembio.1528 · 2014
Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis
10.1371/journal.pone.0119264 · 2015
End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design
10.1021/acs.chemrev.9b00055 · 2019
Unraveling the allosteric inhibition mechanism of PTP1B by free energy calculation based on umbrella sampling
10.1021/ci300526u · 2013
Uncompetitive allosteric inhibition of PTP1B by BP-1-102 reveals a potential dual-target strategy toward the PTP1B-STAT3 oncogenic axis: biochemical and computational evidence
10.1021/acsmedchemlett.6c00242 · 2026
Kinetic compatibility as a predictor of PTP1B inhibitor combination outcomes: an integrated experimental and computational study
10.1002/cmdc.70446 · 2026
Allosteric inhibition of PTP1B by a nonpolar terpenoid
10.1021/acs.jpcb.2c05423 · 2022
The structural biology of Bcl-x(L)
10.3390/ijms20092234 · 2019
Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival
10.1074/jbc.m109.095232 · 2010
Unified understanding of folding and binding mechanisms of globular and intrinsically disordered proteins
10.1007/s12551-017-0346-7 · 2018
Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL
10.1021/bi901171n · 2009
Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival Bcl-2 family proteins
10.1016/j.csbj.2023.07.017 · 2023
Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism
10.1038/s41467-025-65509-1 · 2025
AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility
10.1002/jcc.21256 · 2009
Development and testing of a general amber force field
10.1002/jcc.20035 · 2004
ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution
10.1021/acs.jctc.9b00591 · 2020
AmberTools
10.1021/acs.jcim.3c01153 · 2023
MDAnalysis: a toolkit for the analysis of molecular dynamics simulations
10.1002/jcc.21787 · 2011
VMD: visual molecular dynamics
10.1016/0263-7855(96)00018-5 · doi-reference